Showing 4681-4690 of 8213 results for "".
- Arcutis to Accelerate Program for ARQ-151 for Atopic Dermatitishttps://practicaldermatology.com/news/arcutis-to-accelerate-program-for-arq-151-for-atopic-dermatitis/2460520/Arcutis Biotherapeutics, Inc. plans to advance its program to develop ARQ-151 (topical roflumilast cream) for the treatment of atopic dermatitis into Phase 3 clinical trials without conducting the previously planned Phase 2b atopic dermatitis trial. The decision follows an End
- Medicine X Launches Eczema Xplained Patient Story To Drive Understanding and Awareness of ADhttps://practicaldermatology.com/news/medicine-x-launches-eczema-xplained-patient-story-to-drive-understanding-and-awareness-of-ad/2460519/Medicine X today is launching Eczema Xplained, its first illustrated story in the U.S. on atopic dermatitis, the most comm
- Keystone Dermatology Virtual CME Conference Coming October 8-10https://practicaldermatology.com/news/keystone-dermatology-virtual-cme-conference-coming-october-8-10/2460517/Pennsylvania Dermatology Physician Assistants has transitioned its annual meeting to a virtual format. Registration is now open for Keystone Dermatology Virtual CME Conference, to be held October 8-10, 2020. Early bird registration ends September 8. Topics to be
- Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areatahttps://practicaldermatology.com/news/arena-pharmaceuticals-announces-first-subject-dosed-in-phase-2-trial-evaluating-etrasimod-in-alopecia-areata/2460515/The first subject has been dosed in
- Revance Commercial Infrastructure to Launch RHA Collection of Dermal Fillershttps://practicaldermatology.com/news/revance-commercial-infrastructure-to-launch-rha-collection-of-dermal-fillers/2460512/Revance Therapeutics, Inc. will begin introducing the RHA Collection of dermal fillers, Resilient Hyaluronic Acid, and the HintMD financial technology platform, in the United States in September. The RHA Collection of derma
- Positive Phase 3 Results for Dermavant's Tapinarof Cream for Plaque Psoriasishttps://practicaldermatology.com/news/positive-phase-3-results-results-for-dermavants-tapinarof-cream-for-plaque-psoriasis/2460511/Dermavant Sciences shared positive results from PSOARING 1 and PSOARING 2, two identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies to evaluate the efficacy and safety of tapinarof cream 1% in adult patients with plaque psoriasis. In both PSOARING 1 (N
- Verrica Pharmaceuticals Names New Clinical and Drug Development Leadership Team Membershttps://practicaldermatology.com/news/verrica-pharmaceuticals-names-new-clinical-and-drug-development-leadership-team-members/2460509/Verrica Pharmaceuticals Inc. announced key appointments to its drug development team. Current Board of Directors member Gary Goldenberg, MD, a thought leader in the field of dermatology, stepped down to become Verrica’s Chief Medical Officer, effective August 1, 2020. Dr. Law
- Skin Diseases Highly Common in Older Adultshttps://practicaldermatology.com/news/skin-diseases-highly-common-in-older-adults/2460507/Fully 80 percent of adults aged 70 to 93 have at least one skin disease that required treatment, and the most common conditions were fungal skin infections, rosacea, actinic keratosis, and eczema, according to a new study in the 
- ISDIN Sunscreen Survey: Just 37% of the US Population Protects Themselves from the Sun on a Daily Basishttps://practicaldermatology.com/news/isdin-sunscreen-survey-just-37-of-the-us-population-protects-themselves-from-the-sun-on-a-daily-basis/2460505/While half of the US population is aware of the importance of sun protection and state they use sun protection during sun exposure, only 37 percent are using it on a daily basis, according to new survey from ISDIN. In the s
- Estée Lauder Companies and Atropos Therapeutics Partner to Discover Botanical Senomodulatorshttps://practicaldermatology.com/news/estee-lauder-companies-and-atropos-therapeutics-partner-to-discover-senomodulators/2460500/The Estée Lauder Companies and Atropos Therapeutics are joining forces to discover botanical senomodulators or senescence-modulating chemicals. Atropos Therapeutics Inc. has a proprietary platform to identify and develop senescence-modu